{
    "organizations": [],
    "uuid": "6d7e5894605925df3e214707822e8a5836ccaeff",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pfizer-receives-breakthrough-thera/brief-pfizer-receives-breakthrough-therapy-designation-from-fda-for-atopic-dermatitis-treatment-pf-04965842-idUSASB0C5OB",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Receives Breakthrough Therapy Designation From FDA For Atopic Dermatitis Treatment, PF-04965842",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - Pfizer Inc:\n* PFIZER RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR PF-04965842, AN ORAL JAK1 INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-14T21:37:00.000+02:00",
    "crawled": "2018-02-15T20:58:43.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "pfizer",
        "inc",
        "pfizer",
        "receives",
        "breakthrough",
        "therapy",
        "designation",
        "fda",
        "oral",
        "jak1",
        "inhibitor",
        "treatment",
        "patient",
        "atopic",
        "dermatitis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}